Surgery – Blood drawn and replaced or treated and returned to body – Constituent removed from blood and remainder returned to body
Patent
1988-08-10
1990-09-11
Cannon, Alan W.
Surgery
Blood drawn and replaced or treated and returned to body
Constituent removed from blood and remainder returned to body
604 4, 604 28, 530412, 2101952, 210259, 210632, 21050023, A61M 3700
Patent
active
049558579
ABSTRACT:
A new therapy for cancer which involves removal from circulation of several nonessentials amino acids, some essential amino acids and folic acid simultaneously and continuously for long-term therapy is disclosed. The therapy uses extracorporeal blood circulation using a multi-enzyme bioreactor without any of the side effects associated with the direct intravenous infusion of these enzymes. The combined depletion of folates and essential and nonessential amino acids produces a synergistic effect in treating the cancerous tissue, and serves to minimize or reduce the adaptation process of cancer cells, especially over a longer range continuous therapy.
REFERENCES:
patent: 3865726 (1975-02-01), Chibata et al.
patent: 3963613 (1976-06-01), Chibata et al.
patent: 4248704 (1981-02-01), Marconi et al.
patent: 4356267 (1982-10-01), Callegaro et al.
patent: 4361484 (1982-11-01), Larsson et al.
patent: 4450153 (1984-05-01), Hopkins
patent: 4692411 (1987-09-01), Ghose
patent: 4696670 (1987-09-01), Ohnishi et al.
patent: 4708713 (1987-11-01), Lentz
patent: 4846786 (1989-07-01), Freed et al.
Pages vi through 103 of book entitled "Enzymes as Drugs" edited by John S. Holcenberg of the Medical College of Wisconsin and Joseph Roberts of Sloan Kettering Institute for Cancer Research dated Jan. 1981.
LandOfFree
Multi-enzyme bioreactor therapy for cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multi-enzyme bioreactor therapy for cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multi-enzyme bioreactor therapy for cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1181595